M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.375, pp.1823-1833, 2016.

M. Reck, F. Taylor, J. R. Penrod, M. Derosa, L. Morrissey et al., Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study, J. Thorac. Oncol, vol.13, pp.194-204, 2018.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. E. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.373, pp.123-135, 2015.

P. Goldstraw, K. Chansky, J. Crowley, R. Rami-porta, H. Asamura et al., The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, J. Thorac. Oncol, vol.11, pp.39-51, 2016.

J. Pignon, H. Tribodet, G. V. Scagliotti, J. Douillard, F. A. Shepherd et al., Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group, J. Clin. Oncol, vol.26, pp.3552-3559, 2008.

P. M. Forde, J. E. Chaft, K. N. Smith, V. Anagnostou, T. R. Cottrell et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.375, pp.1823-1833, 2016.

M. Reck, F. Taylor, J. R. Penrod, M. Derosa, L. Morrissey et al., Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study, J. Thorac. Oncol, vol.13, pp.194-204, 2018.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. E. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.373, pp.123-135, 2015.

P. Goldstraw, K. Chansky, J. Crowley, R. Rami-porta, H. Asamura et al., The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, J. Thorac. Oncol, vol.11, pp.39-51, 2016.

J. Pignon, H. Tribodet, G. V. Scagliotti, J. Douillard, F. A. Shepherd et al., Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group, J. Clin. Oncol, vol.26, pp.3552-3559, 2008.

P. M. Forde, J. E. Chaft, K. N. Smith, V. Anagnostou, T. R. Cottrell et al., Neoadjuvant PD-1 Blockade in Resectable Lung Cancer, N. Engl. J. Med, vol.378, 1976.

S. J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami et al., Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N. Engl. J. Med, vol.379, pp.2342-2350, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02284390

M. Francart, J. Lambert, A. M. Vanwynsberghe, E. W. Thompson, M. Bourcy et al., Epithelial-mesenchymal plasticity and circulating tumor cells: Travel companions to metastases, Dev. Dyn, vol.247, pp.432-450, 2018.

N. Tsoukalas, E. Aravantinou-fatorou, M. Tolia, C. Giaginis, M. Galanopoulos et al., Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer, Anticancer Res, vol.37, pp.1773-1778, 2017.

P. G. Santamaria, G. Moreno-bueno, F. Portillo, and A. Cano, EMT: Present and future in clinical oncology, Mol. Oncol, vol.11, pp.718-738, 2017.

A. Dongre and R. A. Weinberg, New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer, Nat. Rev. Mol. Cell Biol, vol.20, pp.69-84, 2019.

M. Dauphin, C. Barbe, S. Lemaire, B. Nawrocki-raby, E. Lagonotte et al., Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas, Lung Cancer, vol.81, pp.117-122, 2013.

B. Du and J. S. Shim, Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer, Molecules, vol.21, p.965, 2016.

V. Mittal, Epithelial Mesenchymal Transition in Aggressive Lung Cancers, Adv. Exp. Med. Biol, vol.890, pp.37-56, 2016.

Y. Manjunath, S. V. Upparahalli, D. M. Avella, C. B. Deroche, E. T. Kimchi et al., PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer, Cancers, vol.11, 2019.

R. Büttner, J. R. Gosney, B. G. Skov, J. Adam, N. Motoi et al., Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer, J. Clin. Oncol, vol.35, pp.3867-3876, 2017.

A. Lafuente-sanchis, Á. Zúñiga, M. Estors, N. J. Martínez-hernández, A. Cremades et al., Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients with Non-Small-Cell Lung Cancer, Clin. Lung Cancer, vol.18, pp.109-116, 2017.

M. Z. Baptista, L. O. Sarian, S. F. Derchain, G. A. Pinto, and J. Vassallo, Prognostic significance of PD-L1 and PD-L2 in breast cancer, Hum. Pathol, vol.47, pp.78-84, 2016.

R. Brody, Y. Zhang, M. Ballas, M. K. Siddiqui, P. Gupta et al., PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review, Lung Cancer, vol.112, pp.200-215, 2017.

J. Zhang, J. Gao, Y. Li, J. Nie, L. Dai et al., Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics, Thorac. Cancer, vol.6, pp.534-538, 2015.

A. D'incecco, M. Andreozzi, V. Ludovini, E. Rossi, A. Capodanno et al., PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, Br. J. Cancer, vol.112, pp.95-102, 2015.

G. Lin, X. Fan, W. Zhu, C. Huang, W. Zhuang et al., Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer, Oncotarget, vol.8, pp.83986-83994, 2017.

H. Kim, H. J. Kwon, S. Y. Park, Y. Park, E. Park et al., Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer, PLoS ONE, vol.13, 2018.

A. Soltermann, V. Tischler, S. Arbogast, J. Braun, N. Probst-hensch et al., Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer, Clin. Cancer Res, vol.14, pp.7430-7437, 2008.

S. Al-saad, K. Al-shibli, T. Donnem, M. Persson, R. M. Bremnes et al., The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer, Br. J. Cancer, vol.99, pp.1476-1483, 2008.

L. Chen, Y. Xiong, J. Li, X. Zheng, Q. Zhou et al., PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer, Cell Physiol. Biochem. Int. J. Exp. Cell Physiol. Biochem. Pharmacol, vol.42, pp.2267-2280, 2017.

A. Alsuliman, D. Colak, O. Al-harazi, H. Fitwi, A. Tulbah et al., Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells, Mol. Cancer, vol.14, p.149, 2015.

A. Polónia, R. Pinto, J. F. Cameselle-teijeiro, F. C. Schmitt, and J. Paredes, Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer, J. Clin. Pathol, vol.70, pp.860-867, 2017.

C. Ock, S. Kim, B. Keam, M. Kim, T. M. Kim et al., PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma, Oncotarget, vol.7, pp.15901-15914, 2016.

A. Asgarova, K. Asgarov, Y. Godet, P. Peixoto, A. Nadaradjane et al., PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

M. Z. Noman, B. Janji, A. Abdou, M. Hasmim, S. Terry et al., The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200

F. Li, T. Zhu, Y. Yue, X. Zhu, J. Wang et al., Preliminary mechanisms of regulating PD-L1 expression in non-small cell lung cancer during the EMT process, Oncol. Rep, vol.40, pp.775-782, 2018.

S. C. Tripathi, H. L. Peters, A. Taguchi, H. Katayama, H. Wang et al., Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome, Proc. Natl. Acad. Sci, vol.113, pp.1555-1564, 2016.

S. Hendry, D. J. Byrne, G. M. Wright, R. J. Young, S. Sturrock et al., Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer, J. Thorac. Oncol, vol.13, pp.367-376, 2018.

L. A. Byers, L. Diao, J. Wang, P. Saintigny, L. Girard et al., An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance, Clin. Cancer Res, vol.19, pp.279-290, 2013.

J. T. Chang, .. Lee, Y. M. Huang, and R. S. , The impact of the Cancer Genome Atlas on lung cancer, Transl. Res. J. Lab. Clin. Med, vol.166, pp.568-585, 2015.

J. Gao, B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal, issue.6, 2013.

M. Goldman, B. Craft, M. Hastie, K. Repe?ka, A. Kamath et al., The UCSC Xena platform for public and private cancer genomics data visualization and interpretation, 2019.

H. Ishii, K. Azuma, A. Kawahara, N. Matsuo, T. Tokito et al., Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy, Oncotarget, vol.8, pp.61618-61625, 2017.

E. Paulsen, T. K. Kilvaer, M. R. Khanehkenari, S. Al-saad, S. M. Hald et al., Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach, Clin. Lung Cancer, vol.18, pp.220-233, 2017.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2019 by the authors. Licensee MDPI